Abstract
As enabling technology, the development and application of multicomponent reactions (MCRs) are now an integral part of the work of any major medical research unit. Targeted MCR approaches focused on specific antimitotic pathways afford new solutions for the medicinal chemistry of the XXI century. In this review, the contribution of these procedures to the discovery of antimitotic drugs that are currently in clinical trials or already in the market is discussed.
Keywords: Antimitotic, Biginelli, Aurora kinases, KSP, Multicomponent reactions, Ugi.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Multicomponent Reactions in Antimitotic Drug Discovery
Volume: 14 Issue: 20
Author(s): Angel Cores, Carlos Carbajales and Alberto Coelho
Affiliation:
Keywords: Antimitotic, Biginelli, Aurora kinases, KSP, Multicomponent reactions, Ugi.
Abstract: As enabling technology, the development and application of multicomponent reactions (MCRs) are now an integral part of the work of any major medical research unit. Targeted MCR approaches focused on specific antimitotic pathways afford new solutions for the medicinal chemistry of the XXI century. In this review, the contribution of these procedures to the discovery of antimitotic drugs that are currently in clinical trials or already in the market is discussed.
Export Options
About this article
Cite this article as:
Cores Angel, Carbajales Carlos and Coelho Alberto, Multicomponent Reactions in Antimitotic Drug Discovery, Current Topics in Medicinal Chemistry 2014; 14 (20) . https://dx.doi.org/10.2174/1568026614666141127115130
DOI https://dx.doi.org/10.2174/1568026614666141127115130 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Drug Targets - Infectious Disorders Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Current HIV Research Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia
Current Pharmaceutical Design Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma
Current Gene Therapy Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry